ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,740.26
      1.35%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. Amneal Pharmaceuticals Holding Co (AMRX)

      7. Amneal Pharmaceuticals Holding Co (AMRX) News

      AMRX

      Amneal Pharmaceuticals (AMRX)

      Amneal Pharmaceuticals Holding Co
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:AMRX
      DateTimeSourceHeadlineSymbolCompany
      05/03/20246:14AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
      05/03/20246:00AMBusiness WireAmneal Reports First Quarter 2024 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
      04/24/20248:00AMBusiness WireAmneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid OverdoseNYSE:AMRXAmneal Pharmaceuticals Holding Co
      04/16/20248:00AMBusiness WireAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable MedicineNYSE:AMRXAmneal Pharmaceuticals Holding Co
      04/10/20248:00AMBusiness WireAmneal to Report First Quarter 2024 Results on May 3, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/28/20244:05PMBusiness WireAmneal to Ring the Nasdaq Closing Bell on April 2, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/25/20244:05PMBusiness WireAmneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/22/20248:01AMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/22/20248:01AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/06/20245:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/06/20245:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/05/20244:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/05/20244:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/01/20246:13AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
      03/01/20246:00AMBusiness WireAmneal Reports Fourth Quarter and Full Year 2023 Financial ResultsNYSE:AMRXAmneal Pharmaceuticals Holding Co
      02/29/20244:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
      02/27/20248:00AMBusiness WireAmneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203NYSE:AMRXAmneal Pharmaceuticals Holding Co
      02/13/20248:00AMBusiness WireAmneal to Participate at Upcoming Investor ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
      02/08/20244:05PMGlobeNewswire Inc.Amneal Announces Complete Response Resubmission for IPX203 New Drug ApplicationNYSE:AMRXAmneal Pharmaceuticals Holding Co
      01/31/20244:05PMBusiness WireAmneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024NYSE:AMRXAmneal Pharmaceuticals Holding Co
      01/10/20248:00AMBusiness WireAmneal Launches Complex Generic Fluorometholone Ophthalmic SuspensionNYSE:AMRXAmneal Pharmaceuticals Holding Co
      01/04/20244:05PMBusiness WireAmneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023NYSE:AMRXAmneal Pharmaceuticals Holding Co
      12/26/20234:10PMEdgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNYSE:AMRXAmneal Pharmaceuticals Holding Co
      12/26/20234:05PMEdgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NYSE:AMRXAmneal Pharmaceuticals Holding Co
      12/21/20238:00AMBusiness WireAmneal to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNYSE:AMRXAmneal Pharmaceuticals Holding Co
      12/15/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:AMRXAmneal Pharmaceuticals Holding Co
      12/15/20234:06PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
      12/15/20234:05PMBusiness WireAmneal Announces Move to NasdaqNYSE:AMRXAmneal Pharmaceuticals Holding Co
      12/07/20238:00AMBusiness WireAmneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)NYSE:AMRXAmneal Pharmaceuticals Holding Co
      12/01/20234:15PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:AMRXAmneal Pharmaceuticals Holding Co
       Showing the most relevant articles for your search:NYSE:AMRX